You can be fairly certain that the patent was assigned to Sanofi in exchange for a portion of the revenues or profits, thus generating a return for the investment the Walter Reed Army Institute for Research made. As to the selling price of the vaccine, that is a different matter. Unlike most western countries, the US doesn't impose price controls on medications, regardless of patent status.